Neurocrine Biosciences’ new drug may cost patients taking recommended dose twice as much as expected

Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about $64,000 a year.